23/02/2026
New 2026 NICE Update on Initial Drug Therapy in Type 2 Diabetes Detailed Thread
1️⃣ Big Shift in Philosophy
This is no longer just about lowering HbA1c.
The new guidance prioritises:
• Cardiovascular protection
• Renal protection
• Individualised treatment
• Early combination therapy
Glucose control is important but outcomes matter more.
2️⃣ First-Line Therapy (No Major Comorbidities)
For most adults:
✅ Modified-release metformin
PLUS
✅ An SGLT-2 inhibitor
If metformin cannot be used → start SGLT-2 inhibitor alone.
➡️ This is a major shift from traditional “metformin first, add later.”
3️⃣ Why SGLT-2 So Early?
Because evidence now strongly supports:
• Reduction in heart failure hospitalization
• Slowing CKD progression
• Cardiovascular mortality benefit
• Weight reduction
• Low hypoglycaemia risk
This class is now foundational therapy.
4️⃣ If the Patient Has Heart Failure
Start immediately:
✅ Metformin
✅ SGLT-2 inhibitor
If metformin contraindicated → SGLT-2 alone.
HF benefit drives this decision independent of HbA1c.
5️⃣ If Atherosclerotic CVD Is Present
Initial therapy can include:
✅ Metformin
✅ SGLT-2 inhibitor
✅ Subcutaneous semaglutide (GLP-1 RA)
If Yes 👉🏻 GLP-1 RA can now be started upfront in ASCVD.
This reflects strong CV outcome trial data.
6️⃣ Early-Onset Type 2 Diabetes
(Younger patients, aggressive phenotype)
Start:
✅ Metformin
✅ SGLT-2 inhibitor
Consider adding:
• GLP-1 receptor agonist
• Tirzepatide
This group often needs earlier intensification.
7️⃣ Obesity + Type 2 Diabetes
Initial therapy:
✅ Metformin
✅ SGLT-2 inhibitor
Weight-neutral or weight-reducing strategies are preferred.
Avoid agents that promote weight gain unless necessary.
8️⃣ Chronic Kidney Disease (CKD)
Treatment depends on eGFR:
🔹 eGFR >30 → Metformin + SGLT-2
🔹 eGFR 20–30 → Dapagliflozin or Empagliflozin + DPP-4 inhibitor
🔹 eGFR
